|
US7393682B1
(en)
|
1993-03-19 |
2008-07-01 |
The Johns Hopkins University School Of Medicine |
Polynucleotides encoding promyostatin polypeptides
|
|
AU686660B2
(en)
*
|
1993-08-11 |
1998-02-12 |
Jenner Technologies |
Prostatic cancer vaccine
|
|
US7354587B1
(en)
|
1994-07-06 |
2008-04-08 |
Immunomedics, Inc. |
Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
|
|
US5798100A
(en)
*
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
|
EP0796280B1
(de)
*
|
1994-12-28 |
2003-03-26 |
University Of Kentucky |
Monoklonaler anti-idiotypischer antikörper 3h1 aus maus
|
|
US6949244B1
(en)
|
1995-12-20 |
2005-09-27 |
The Board Of Trustees Of The University Of Kentucky |
Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
|
|
US5763216A
(en)
*
|
1995-06-07 |
1998-06-09 |
The United States Of America As Represented By The Department Of Health & Human Services |
Gene encoding a human reduced folate carrier (RFC)
|
|
US5716788A
(en)
*
|
1995-06-07 |
1998-02-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Antibodies to human reduced folate carrier protein
|
|
WO1997023237A1
(en)
|
1995-12-22 |
1997-07-03 |
Immunomedics, Inc. |
Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
|
|
WO1997034636A1
(en)
|
1996-03-20 |
1997-09-25 |
Immunomedics, Inc. |
Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
|
|
US20020041872A1
(en)
|
1996-04-12 |
2002-04-11 |
Malaya Chatterjee |
Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
|
|
US6235280B1
(en)
|
1996-04-12 |
2001-05-22 |
Malaya Chatterjee |
Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
|
|
US6090381A
(en)
|
1997-02-11 |
2000-07-18 |
Immunomedics, Inc. |
Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
|
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
US6274143B1
(en)
|
1997-06-13 |
2001-08-14 |
Malaya Chatterjee |
Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
|
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
|
ATE421888T1
(de)
*
|
1997-08-13 |
2009-02-15 |
Uab Research Foundation |
Impfung durch topische verwendung genetischer vektoren
|
|
CA2310252A1
(en)
*
|
1998-03-06 |
1999-09-10 |
Imclone Systems Incorporated |
Active immunization against angiogenesis-associated antigens
|
|
US7157418B1
(en)
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
US6652836B2
(en)
|
1998-10-15 |
2003-11-25 |
Fluoroprobe, Inc. |
Method for viewing tumor tissue located within a body cavity
|
|
ES2639020T3
(es)
|
1998-11-27 |
2017-10-25 |
Ucb Pharma S.A. |
Composiciones y métodos para incrementar la mineralización de la substancia ósea
|
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
|
CZ303272B6
(cs)
|
1999-01-07 |
2012-07-11 |
Zymogenetics, Inc. |
Farmaceutický prostredek obsahující fúzní protein, izolovaná molekula polynukleotidu, expresní vektor, kultivovaná bunka, zpusob prípravy polypeptidu a izolovaný polypeptid
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
DE60042785D1
(de)
|
1999-06-09 |
2009-10-01 |
Immunomedics Inc |
Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
|
|
DE60034564T2
(de)
|
1999-07-07 |
2007-12-27 |
Zymogenetics, Inc., Seattle |
Menschlicher cytokinrezeptor
|
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
|
RU2172182C1
(ru)
*
|
2000-07-27 |
2001-08-20 |
Бритов Василий Александрович |
Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
|
|
WO2002036578A2
(en)
|
2000-10-31 |
2002-05-10 |
Lynn Bonham |
Triazine derivatives as lpaat-b inhibitors and uses thereof
|
|
US6890734B2
(en)
|
2000-11-10 |
2005-05-10 |
Schering Corporation |
Nucleic acids encoding a cytokine receptor complex
|
|
AU2002238052A1
(en)
|
2001-02-20 |
2002-09-04 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
AT410637B
(de)
*
|
2001-06-01 |
2003-06-25 |
Igeneon Krebs Immuntherapie |
Verwendung von polyklonalen immunglobulinen
|
|
WO2003037346A1
(en)
|
2001-10-31 |
2003-05-08 |
Cell Therapeutics, Inc. |
6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
JP2006516883A
(ja)
|
2002-09-19 |
2006-07-13 |
アメリカ合衆国 |
P.アリアシポリペプチド、ユウガイサシチョウバエポリペプチド、および使用法
|
|
US7419984B2
(en)
|
2002-10-17 |
2008-09-02 |
Cell Therapeutics, Inc. |
Pyrimidines and uses thereof
|
|
DE60327366D1
(de)
|
2002-10-29 |
2009-06-04 |
Fundacao Oswaldo Cruz |
Lutzomyia longipalpis-polypeptide und verwendungsverfahren
|
|
US6875781B2
(en)
|
2003-04-04 |
2005-04-05 |
Cell Therapeutics, Inc. |
Pyridines and uses thereof
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8435539B2
(en)
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8562988B2
(en)
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US8491914B2
(en)
*
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
EP2465534B1
(de)
|
2004-06-10 |
2017-03-29 |
Omeros Corporation |
Verfahren zur Behandlung von Leiden in Zusammenhang mit MASP-2-abhängiger Komplementaktivierung
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
GB0412966D0
(en)
|
2004-06-10 |
2004-07-14 |
Univ Leicester |
Genetically modified non-human mammals and cells
|
|
PL1810026T3
(pl)
|
2004-10-06 |
2018-08-31 |
Mayo Foundation For Medical Education And Research |
B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
|
|
WO2006086396A2
(en)
|
2005-02-08 |
2006-08-17 |
Zymogenetics, Inc. |
Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
CN101171034B
(zh)
|
2005-03-03 |
2014-06-18 |
免疫医疗公司 |
人源化l243抗体
|
|
EP3683230A1
(de)
|
2005-05-12 |
2020-07-22 |
ZymoGenetics, Inc. |
Zusammensetzungen und verfahren zur modulation von immunsystemreaktionen
|
|
CN101248090A
(zh)
*
|
2005-06-03 |
2008-08-20 |
威德尼斯公司 |
针对通用肿瘤抗原的多克隆抗血清
|
|
KR20080056714A
(ko)
|
2005-08-09 |
2008-06-23 |
지모제넥틱스, 인코포레이티드 |
TACI―Ig 융합 분자를 사용하여 B―세포 악성종양을치료하는 방법
|
|
US8808696B2
(en)
|
2005-08-09 |
2014-08-19 |
Ares Trading S.A. |
Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
|
|
EP2674440B1
(de)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Polyvalente bioaktive anordnungen auf immunglobulinbasis
|
|
CN101426536A
(zh)
|
2006-01-20 |
2009-05-06 |
妇女儿童健康研究院公司 |
治疗、预防和诊断骨病变的方法
|
|
DE602007009954D1
(de)
|
2006-03-22 |
2010-12-02 |
Viral Logic Systems Technology |
Verfahren zur identifizierung von polypeptid-targets
|
|
WO2007134326A2
(en)
|
2006-05-15 |
2007-11-22 |
Ares Trading S.A. |
Methods for treating autoimmune diseases using a taci-ig fusion molecule
|
|
US8377448B2
(en)
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
|
WO2008088582A2
(en)
|
2006-08-04 |
2008-07-24 |
Mayo Foundation For Medical Education And Research |
Methods and materials related to trail isoforms
|
|
US7858759B2
(en)
|
2007-10-04 |
2010-12-28 |
Zymogenetics, Inc. |
Anti-zB7H6 antibody-drug conjugates
|
|
US8236318B2
(en)
*
|
2007-11-07 |
2012-08-07 |
Celldex Therapeutics Inc. |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
|
CN101918437B
(zh)
|
2007-11-21 |
2013-08-14 |
罗斯基勒大学 |
具有冰结合活性的多肽
|
|
US8552155B2
(en)
|
2008-05-28 |
2013-10-08 |
Mayo Foundation For Medical Education And Research |
Anti-Pyk2 antibodies
|
|
WO2010022225A1
(en)
|
2008-08-20 |
2010-02-25 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) vaccines for cancer therapy
|
|
PL3912643T3
(pl)
|
2009-02-13 |
2023-01-23 |
Immunomedics Inc. |
Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
|
|
AU2010266129B2
(en)
|
2009-07-02 |
2016-04-14 |
Massachusetts Institute Of Technology |
Compositions and methods for diagnosing and/or treating influenza infection
|
|
US20120269765A1
(en)
|
2009-07-24 |
2012-10-25 |
Garcia K Christopher |
Cytokine compositions and methods of use thereof
|
|
EP3150635A3
(de)
|
2009-10-16 |
2017-06-21 |
Omeros Corporation |
Verfahren zur behandlung ausgebreiteter intravaskulärer gerinnung durch hemmung masp-2-abhängiger komplementaktivierung
|
|
EP2497498A4
(de)
|
2009-11-05 |
2013-04-17 |
Univ Osaka |
Therapeutischer wirkstoff für autoimmunerkrankungen oder allergien sowie verfahren zum screening nach dem therapeutischen wirkstoff
|
|
WO2011159826A2
(en)
|
2010-06-15 |
2011-12-22 |
Vertex Pharmaceuticals Incorporated |
Hcv ns5b protease mutants
|
|
AU2011305371B2
(en)
|
2010-09-21 |
2015-05-21 |
Massachusetts Institute Of Technology |
Human-adapted HA polypeptides, vaccines, and influenza treatment
|
|
AU2011312178B2
(en)
|
2010-10-04 |
2016-05-12 |
Massachusetts Institute Of Technology |
Hemagglutinin polypeptides, and reagents and methods relating thereto
|
|
CA2815416A1
(en)
|
2010-10-21 |
2012-04-26 |
Vertex Pharmaceuticals Incorporated |
Biomarkers for hcv infected patients
|
|
WO2012057765A1
(en)
|
2010-10-28 |
2012-05-03 |
The Board Of Regents Of The University Of Texas System |
Recombinant anti-cd19 monoclonal antibodies
|
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
DK2694108T3
(en)
|
2011-04-08 |
2018-08-20 |
Univ Leicester |
METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
|
|
AU2012271336B2
(en)
|
2011-06-17 |
2017-03-02 |
University Of Tennessee Research Foundation |
Group A streptococcus multivalent vaccine
|
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
|
US9192664B2
(en)
|
2011-12-05 |
2015-11-24 |
Immunomedics, Inc. |
Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
|
|
CA2866185C
(en)
|
2012-03-23 |
2021-04-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
|
NZ629675A
(en)
|
2012-04-06 |
2017-02-24 |
Omeros Corp |
Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
|
|
AU2013260123A1
(en)
|
2012-05-10 |
2014-11-13 |
Massachusetts Institute Of Technology |
Agents for influenza neutralization
|
|
PT2861246T
(pt)
|
2012-06-18 |
2021-04-05 |
Univ Leicester |
Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
|
|
WO2014015217A1
(en)
|
2012-07-19 |
2014-01-23 |
Vertex Pharmaceuticals Incorporated |
Biomarkers for hcv infected patients
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
US20240148873A1
(en)
|
2012-12-13 |
2024-05-09 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US12310958B2
(en)
|
2012-12-13 |
2025-05-27 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
|
WO2014116865A1
(en)
|
2013-01-24 |
2014-07-31 |
Mayo Foundation For Medical Education And Research |
Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
|
|
WO2014124319A2
(en)
|
2013-02-07 |
2014-08-14 |
Massachusetts Institute Of Technology |
Human adaptation of h5 influenza
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
MX2015011945A
(es)
|
2013-03-14 |
2015-12-01 |
Shire Human Genetic Therapies |
Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
|
|
EA201591993A1
(ru)
|
2013-05-23 |
2016-05-31 |
Шир Хьюман Дженетик Терапис, Инк. |
Лечение склеродермии с применением комбинированной терапии антителами анти-ccl2 и анти-loxl2
|
|
US10526375B2
(en)
|
2013-06-05 |
2020-01-07 |
Massachusetts Institute Of Technology |
Human Adaptation of H7 HA
|
|
WO2014202089A2
(en)
|
2013-06-18 |
2014-12-24 |
Roskilde Universitet |
Variants of anti-freeze polypeptides
|
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
EP3470081A1
(de)
|
2013-10-01 |
2019-04-17 |
Mayo Foundation for Medical Education and Research |
Verfahren zur behandlung von krebs bei patienten mit erhöhten bim-werten
|
|
RS61351B1
(sr)
|
2013-10-17 |
2021-02-26 |
Omeros Corp |
Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
|
|
US20150174242A1
(en)
|
2013-12-19 |
2015-06-25 |
Mayo Foundation For Medical Education And Research |
Monovalent anti-cd3 adjuvants
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
EP4011910A1
(de)
|
2014-04-03 |
2022-06-15 |
IGM Biosciences, Inc. |
Modifizierte j-kette
|
|
US9833512B2
(en)
|
2014-04-09 |
2017-12-05 |
Mayo Foundation For Medical Education And Research |
Blocking IL-9 signaling in conjunction with chemotherapy to treat cancer
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
US10610570B2
(en)
|
2014-07-09 |
2020-04-07 |
Mayo Foundation For Medical Education And Research |
Treating rotator cuff conditions
|
|
US10517875B2
(en)
|
2014-07-23 |
2019-12-31 |
Mayo Foundation for Medical Engineering and Research |
Targeting DNA-PKcs and B7-H1 to treat cancer
|
|
PL3204018T3
(pl)
|
2014-10-07 |
2022-01-03 |
Immunomedics, Inc. |
Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
|
|
EP3271402B1
(de)
|
2015-03-16 |
2021-04-28 |
Aarhus Universitet |
Antikörper gegen ein extrazelluläres region nbcn1
|
|
EP3286224A4
(de)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
|
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
WO2017011762A1
(en)
|
2015-07-16 |
2017-01-19 |
Mayo Foundation For Medical Education And Research |
Treating rotator cuff conditions
|
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
|
CN117398458A
(zh)
|
2015-11-09 |
2024-01-16 |
奥默罗斯公司 |
用于治疗与masp-2依赖性补体活化相关的病况的方法
|
|
WO2017117130A1
(en)
|
2015-12-28 |
2017-07-06 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
|
|
CA3010593C
(en)
|
2016-01-05 |
2024-02-13 |
University Of Leicester |
Methods for inhibiting fibrosis in a subject in need thereof
|
|
CN108601841A
(zh)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|
|
NZ745531A
(en)
|
2016-03-31 |
2020-09-25 |
Omeros Corp |
Methods for inhibiting angiogenesis in a subject in need thereof
|
|
RU2725292C2
(ru)
|
2016-04-27 |
2020-06-30 |
Иммьюномедикс, Инк. |
Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
|
|
EP3450460B1
(de)
|
2016-04-29 |
2023-07-12 |
Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. |
Multispezifisches bindungskonjugat, entsprechende pharmazeutische zusammensetzungen und verwendung
|
|
WO2018055031A1
(en)
|
2016-09-21 |
2018-03-29 |
Aarhus Universitet |
Acid-base transport inhibitors
|
|
RU2758234C2
(ru)
|
2017-03-27 |
2021-10-26 |
Иммьюномедикс, Инк. |
ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
|
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
TWI818919B
(zh)
|
2017-08-15 |
2023-10-21 |
美商歐米諾斯公司 |
用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法
|
|
WO2019060907A1
(en)
|
2017-09-25 |
2019-03-28 |
Fred Hutchinson Cancer Research Center |
HIGH PERFORMANCE TARGETED IN SITU PANGENOMIC PROFILING
|
|
WO2019090284A1
(en)
|
2017-11-06 |
2019-05-09 |
Mayo Foundation For Medical Education And Research |
Methods and materials for identifying and treating cancers having elevated levels of phosphorylated ubiquitin
|
|
WO2019231935A1
(en)
|
2018-05-29 |
2019-12-05 |
Omeros Corporation |
Masp-2 inhibitors and methods of use
|
|
US12264189B2
(en)
|
2018-10-31 |
2025-04-01 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US12624086B2
(en)
|
2018-10-31 |
2026-05-12 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
|
US12257286B2
(en)
|
2018-10-31 |
2025-03-25 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
BR112022010895A2
(pt)
|
2019-12-04 |
2022-09-06 |
Omeros Corp |
Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
|
|
AU2020395306B2
(en)
|
2019-12-04 |
2025-04-24 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
|
JP7699389B2
(ja)
|
2019-12-04 |
2025-06-27 |
オメロス コーポレーション |
Masp-2阻害剤および使用方法
|
|
US12029736B2
(en)
|
2020-02-25 |
2024-07-09 |
Mediboston Limited |
Camptothecin derivatives and conjugates thereof
|
|
TWI867422B
(zh)
|
2020-03-06 |
2024-12-21 |
美商奥默羅斯公司 |
用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
|
|
EP4221752A4
(de)
|
2020-09-30 |
2024-12-04 |
Dren Bio, Inc. |
Anti-cd94 antikörper und verfahren zu deren verwendung
|
|
US12521444B2
(en)
|
2021-02-25 |
2026-01-13 |
Fortvita Biologics Limited |
Anti-HER2 antibody-drug conjugates and uses thereof
|
|
AU2023313117A1
(en)
|
2022-07-27 |
2025-02-13 |
Mediboston Limited |
Auristatin derivatives and conjugates thereof
|